Virus infections post transplant: Risk and immunity

Transplant Infectious Disease

Volumn 7, Issue 3-4, 2005, Pages 97-98

  Hirsch, H H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD20 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HIGH RISK POPULATION; HLA MATCHING; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; VARICELLA ZOSTER VIRUS; VIRUS DIAGNOSIS; VIRUS INFECTION;

ADULT; CHILD; CYTOMEGALOVIRUS; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; RISK FACTORS; STEM CELL TRANSPLANTATION; VIRUS DISEASES;

EID: 29544446695     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2005.00116.x     Document Type: Editorial

References (12)

1. FISHMAN JA, RUBIN RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741-1751.
2. LJUNGMAN P, BRAND R, EINSELE H, FRASSONI F, NIEDERWIESER D, CORDONNIER C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003: 102: 4255-4260.
3. ROSSINI F, TERRUSZZI E, CAMMAROTA S, et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis 2005: 7: 122-125.
4. LIMAYE AP, COREY L, KOELLE DM, DAVIS CL, BOECKH M. Emergence of ganciclovir-resistant Cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000: 356: 645-649.
5. PAYA C, HUMAR A, DOMINGUEZ E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611-620.
6. BOIVIN G, GOYETTE N, GILBERT C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004: 189: 1615-1618.
7. GREEN M, WEBBER S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003: 50: 1471-1491.
8. COMOLI P, MACCARIO R, LOCATELLI F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005: 5: 1415-1422.
9. BABEL N, GABDRAKHMANOVA L, HAMMER M, et al. Induction of pretransplant EBV infection by blood donor transfusion in EBV seronegative recipients may reduce PTLD risk. Transpl Infect Dis 2005: 7: 133-136.
10. GOURISHANKAR S, MCDERMID JC, JHANGRI GS, PREIKSAITIS JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transpl 2004: 4: 108-115.
11. NEU AM. Indications for varicella vaccination post-transplant. Pediatr Transplant 2005: 9: 141-144.
12. KRONENBERG ABW, WUTHRICH RP, CAO C, et al. Retrospective analysis of varicella zoster virus load in plasma of patients with herpes zoster and disseminated disease. Transpl Infect Dis 2005: 7: 116-121.